Woodline Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Woodline Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-670,867	Closed	-$4.54M	–	1009
2024 Q4	$4.54M	Sell	670,867 -452	-0.1%	-$3.04K	0.03%	504
2024 Q3	$4.42M	Buy	671,319 +6,869	+1%	+$49.2K	0.04%	401
2024 Q2	$4.98M	Buy	+664,450	New	+$5.8M	0.05%	341

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Woodline Partners's RXRX Position: Q1 2025 in Review

Woodline Partners sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 670,867 shares — an estimated $4.54M sold.

Woodline Partners first reported a position in RXRX in Q2 2024 and held it in 3 quarters. The position peaked at $4.98M in Q2 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

Woodline Partners reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Woodline Partners sold 670,867 Recursion Pharmaceuticals shares in Q1 2025, an estimated $4.54M.
Woodline Partners first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 3 quarters.
Woodline Partners's Recursion Pharmaceuticals position peaked at $4.98M in Q2 2024.
336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.